NCT00790842 · REGISTRY CONDITION SEARCH

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: TERMINATED
Registry last update: 2018-10-24

Patients with previously treated multiple myeloma and kidney dysfunction will be treated with lenalidomide and low-dose dexamethasone. Phase I will study the side effects and best dose of lenalidomide when given together with low-dose dexamethasone therapy. After the maximum safe and tolerated dose is found in Phase I, the study will proceed to Phase II. Phase II will study how well the the treatment works in patients with previously treated (relapsed or refractory) multiple myeloma and kidney dysfunction. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with dexamethasone may kill more cancer cells. Lenalidomide and dexamethasone may have different effects in patients who have changes in their kidney function.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants in Phase I Component With Dose Limiting Toxicities During the First Cycle of Therapy

→

outcome · POSTED

Percentage of Participants Who Experience a Response [sCR, CR, VGPR, PR]

→

outcome · POSTED

Overall Survival Time

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Worst Degree Treatment-Related Adverse Events Across All Event Types Per Patient

→

outcome · POSTED

Renal Function Over Time

→

outcome · POSTED

Pharmacokinetics of Lenalidomide in Impaired Renal Function

→

outcome · POSTED

Progression-free Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Diagnosed with previously treated multiple myeloma. * Measurable disease assessed by one of the following ≤21 days prior to registration: * Serum monoclonal protein ≥1 g by protein electrophoresis * Urine monoclonal protein \>200 mg on 24 hour electrophoresis * Serum immunoglobulin free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa to lambda free light chain ratio * Monoclonal bone marrow plasmacytosis ≥30% (evaluable disease) * If both serum and urine m-components are present, both must be followed in order to evaluate response. * All previous cancer therapy including chemotherapy, radiation, hormonal therapy and surgery, must be discontinued ≥2 weeks prior to registration. * Age ≥18 years. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Acceptable organ and marrow function ≤21 days prior to registration: * Absolute neutrophil count (ANC) ≥1000/mm³ * Platelet count ≥75,000/mm³ * Total bilirubin ≤2 mg/dL * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 x upper limit of normal * Renal impairment at baseline as measured by serum creatinine clearance (CrCl) ≤60 mL/min ≤21 days prior to registration. * Females of Childbearing Potential (FCBP) must have a negative pregnancy test within 10-14 days and again within 24 hours of starting Cycle 1 and must use an effective double-method contraception for ≥28 days prior to, during, and for ≥28 days after completion of study therapy. * Able to take required prophylactic anticoagulation. * Able to understand and willingness to sign a written informed consent. * Willing to provide blood samples for research purposes (Mayo Clinic sites only). * If previously received lenalidomide, demonstration of clinical response of any duration or stable disease with progression-free interval of ≥6 months from start of that therapy. Exclusion Criteria: * Concurrent use of other anti-cancer agents or treatments. Growth factors and bisphosphonates are allowed as medically indicated. Steroids may be used with an equivalency of up to 20 mg of Prednisone per day as long as the dose has not been adjusted upwards in past 2 weeks prior to study registration. * Uncontrolled intercurrent illness including, but not limited to, any of the following: * Ongoing or active infection requiring IV antibiotics * Symptomatic congestive heart failure * Unstable angina pectoris * Uncontrolled cardiac arrhythmia * Psychiatric illness/social situation that would limit compliance with study requirements. * Any of the following as this regimen may be harmful to a developing fetus or nursing child: * Pregnant women * Breast-feeding women * Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception. * HIV-positive patients on combination antiretroviral therapy. * Known hypersensitivity to thalidomide or other immunomodulatory drugs. * History of Stevens-Johnson syndrome characterized by a desquamating rash while taking thalidomide or similar drugs. * Other active malignancy except for non melanoma skin cancer or in situ cervical or breast cancer. * Concurrent radiation therapy, except for palliation of a single painful bone lesion or fracture.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Creatinine clearance 30 - 60 mL/min, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
intervention Names
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Anticoagulants
label
Group A - CrCl 30-60 mL/min
type
EXPERIMENTAL
description
Creatinine clearance \< 30 mL/min, not on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
intervention Names
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Anticoagulants
label
Group B, CrCl < 30 mL/min
type
EXPERIMENTAL
description
Creatinine clearance \< 30 mL/min and on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
intervention Names
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Anticoagulants
label
Group C, CrCl < 30 mL/min, on dialysis
type
EXPERIMENTAL

interventions

arm Group Labels
Group A - CrCl 30-60 mL/min
Group B, CrCl < 30 mL/min
Group C, CrCl < 30 mL/min, on dialysis
description
Given by mouth days 1-21 of a 28-day cycle. There is a 7 day rest (days 22-28). Continue until disease progression or unacceptable toxicity.
name
Lenalidomide
other Names
Revlimid
type
DRUG
arm Group Labels
Group A - CrCl 30-60 mL/min
Group B, CrCl < 30 mL/min
Group C, CrCl < 30 mL/min, on dialysis
description
40 mg given by mouth days 1, 8, 15 and 22 of a 28-day cycle. Continue until disease progression or unacceptable toxicity.
name
Dexamethasone
other Names
Decadron
type
DRUG
arm Group Labels
Group A - CrCl 30-60 mL/min
Group B, CrCl < 30 mL/min
Group C, CrCl < 30 mL/min, on dialysis
description
Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.
name
Anticoagulants
other Names
Aspirin
Heparin
Low Molecular Weight Heparin
Coumadin
type
DRUG

Study design

allocation

NON_RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 63
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Dose Limiting Toxicity (DLT) was defined as any of the following events determined by the investigator to be possibly, probably, or definitely related to lenalidomide within the first cycle of therapy irrespective of whether the adverse events resolved: * Grade 3 or higher neutropenia with fever ≥38.5 degrees C * Grade 4 neutropenia ≥7 days * Grade 4 or higher thrombocytopenia * Other non-hematologic Grade 4 or higher adverse event not present prior to starting therapy or not due to underlying cause
measure
Number of Participants in Phase I Component With Dose Limiting Toxicities During the First Cycle of Therapy
time Frame
First cycle of therapy (28 days)
description
Per International Myeloma Working Group criteria, complete response (CR): negative immunofixation of serum and urine, normalization of free light chain (FLC) ratio if at study entry FLC was only measurable non-bone parameter, \<5% plasma cells in bone marrow, disappearance of any soft tissue plasma cytomas; stringent complete response (sCR): all of above, + normal serum FLC ratio in all patients and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; partial response (PR): \>=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \>=90% or to \< 200 mg per 24 hours, \>=50% decrease in difference between involved and uninvolved FLC levels or a 50% decrease in level of involved FLC with 50% decrease in ratio, \>=50% reduction in bone marrow plasma cells, if baseline percentage was \>=30%, \>=50% reduction in size of soft tissue plasmacytoma; very good partial response (VGPR): PR + improvements in serum and urine M-components
measure
Percentage of Participants Who Experience a Response [sCR, CR, VGPR, PR]
time Frame
56 months

secondary Outcomes

description
Overall survival is the time from registration to death from any cause. Patients alive at the time of analysis were censored at the date last known alive.
measure
Overall Survival Time
time Frame
56 months
description
Duration of response was defined as time between the onset of response and disease progression in months, among patients treated at the recommended phase II dose who experienced a response to treatment. Per criteria of the International Myeloma Working Group, progressive disease was defined as one of the following: increase of 25% from best confirmed response in serum M-component, urine M-component, free light chain (FLC), bone marrow plasma cell percentage, or development of new or increase in size of bone lesions or soft tissue plasma cytomas. Development of hypercalcemia that can be attributed solely to the myeloma also constituted progression.
measure
Duration of Response
time Frame
56 months
description
The highest degree of any adverse event experienced by each patient, as assessed by NCI CTCAE Version 4, with an attribution of possibly, probably, or definitely related to treatment. Reportable adverse events included those occurring while on treatment or within 30 days of the end of treatment.
measure
Worst Degree Treatment-Related Adverse Events Across All Event Types Per Patient
time Frame
56 months
description
To describe renal function over time and to evaluate the safety profile of a onetime increase in lenalidomide dose at least 2 cycles after start of treatment due to improved renal function.
measure
Renal Function Over Time
time Frame
56 months
description
To determine the pharmacokinetics of lenalidomide administration in myeloma patients with impaired renal function (pharmacokinetic analysis will be performed in up to 12 consented Mayo Clinic subjects treated during the Phase II component of the trial (only).
measure
Pharmacokinetics of Lenalidomide in Impaired Renal Function
time Frame
56 months
description
Progression-free survival is the time from registration to disease progression or death. Patients alive without disease progression were censored at the time of the last disease assessment.
measure
Progression-free Survival
time Frame
56 months

Full study description

brief Summary: Patients with previously treated multiple myeloma and kidney dysfunction will be treated with lenalidomide and low-dose dexamethasone. Phase I will study the side effects and best dose of lenalidomide when given together with low-dose dexamethasone therapy. After the maximum safe and tolerated dose is found in Phase I, the study will proceed to Phase II. Phase II will study how well the the treatment works in patients with previously treated (relapsed or refractory) multiple myeloma and kidney dysfunction. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with dexamethasone may kill more cancer cells. Lenalidomide and dexamethasone may have different effects in patients who have changes in their kidney function.
detailed Description: Multiple Myeloma (MM) affects approximately 20,000 Americans annually and remains an incurable hematologic malignancy characterized by frequent early response followed by universal treatment relapse necessitating multiple sequential therapeutic regimens. Until recently, few effective therapies existed. Several novel agents for MM have now become available including the immunomodulatory drugs thalidomide, lenalidomide, as well as the proteasome inhibitor, bortezomib. Each of these agents is undergoing extensive clinical evaluation in combination with other therapies to produce unprecedented response rates in newly diagnosed and relapsed MM. Lenalidomide has proven to be a highly effective treatment agent, particularly when used in combination with dexamethasone but is renally excreted and little information is available about its use in myeloma patients with impaired kidney function (20% have renal failure at some time after diagnosis). Defining a safe and effective dose of lenalidomide to use is a critical step in MM treatment. OUTLINE: This is a Phase I, dose-escalation study of lenalidomide followed by a Phase II study. Patients are stratified according to degree of renal dysfunction (moderate \[creatinine clearance 30-60 mL/min\] vs severe \[creatinine clearance \<30 mL/min and does not require dialysis\] vs end-stage renal disease \[creatinine clearance \<30 mL/min and requires dialysis\]). Patients receive oral lenalidomide on days 1-21 and low-dose oral dexamethasone 40 mg on days 1, 8, 15, and 22. There is a 7 day rest (days 22-28) from lenalidomide. Each cycle is 28 days and repeated in the absence of disease progression or unacceptable toxicity. Patients enrolled in the phase II portion of the study will undergo blood sample collection periodically for pharmacokinetic analysis of lenalidomide (Mayo Clinic sites only). After completion of study treatment, patients are followed every 6 months for up to 3 years.

Source references

references

citation
Mikhael J, Manola J, Dueck AC, Hayman S, Oettel K, Kanate AS, Lonial S, Rajkumar SV. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. Blood Cancer J. 2018 Aug 29;8(9):86. doi: 10.1038/s41408-018-0110-7.
pmid
30190454
type
RESULT

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-d660bb45246a0366be10
requested nct id
NCT00790842
primary nct id
NCT00790842
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
740aae7c84df8d8d7492cdefcc2b2003f68ec5956a658e5f87d16bbb7ca5e75f
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-d660bb45246a0366be10
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00790842
occurrences
context exact
NCT00790842
end
11
exact text
NCT00790842
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/652/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
5af7668e9d10fb7a871a71c4469e0d4790bf898d98855ff22569b289eab16358
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice